Findings

What do systematic reviews say?

25 questions · 25 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 44%GRADE not reported 0 · 0%Very low 14 · 56%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA

Serious adverse events (proportion) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azathioprine vs no intervention

Serious adverse events (proportion) · people with primary biliary cholangitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lowered blood pressure vs placebo

Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for altering blood pressure in people with acute subarachnoid haemorrhage 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Induced hypertension vs placebo or no intervention

Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage

It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Interventions for altering blood pressure in people with acute subarachnoid haemorrhage 2021 · Cochrane Headline outcomes only
RR 2.24 [1.01, 4.99]
2 studies · 61 participants
Very low

Intervention vs no intervention or control intervention (control)

Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection

It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).

1 finding from 1 review

Pharmacological interventions for acute hepatitis C infection 2018 · Cochrane Headline outcomes only
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low